mTORC2 promotes cell survival through c-Myc-dependent up-regulation of E2F1

Journal of Cell Biology

Volumn 211, Issue 1, 2015, Pages 105-122

  Zou, Zhipeng ^a   Chen, Juan ^a   Liu, Anling ^a   Zhou, Xuan ^a   Song, Qiancheng ^a   Jia, Chunhong ^a   Chen, Zhenguo ^a   Lin, Jun ^a   Yang, Cuilan ^a   Li, Ming ^a   Jiang, Yu ^b   Bai, Xiaochun ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTAGOMIR; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MICRORNA; MICRORNA 9 2; MICRORNA 9 3P; MYC PROTEIN; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG; 2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; E2F1 PROTEIN, HUMAN; INDOLE DERIVATIVE; MIRN92 MICRORNA, HUMAN; MULTIPROTEIN COMPLEX; MYC PROTEIN, HUMAN; PURINE DERIVATIVE; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER CELL; CELL SPECIFICITY; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; ENZYME MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSCRIPTION INITIATION; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BINDING SITE; CANCER TRANSPLANTATION; GENE EXPRESSION; GENETICS; HEK293 CELL LINE; METABOLISM; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PHYSIOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BASE SEQUENCE; BINDING SITES; CELL LINE, TUMOR; CELL SURVIVAL; E2F1 TRANSCRIPTION FACTOR; GENE EXPRESSION; HEK293 CELLS; HUMANS; INDOLES; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; MULTIPROTEIN COMPLEXES; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS C-MYC; PURINES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; UP-REGULATION;

EID: 84980335951     PISSN: 00219525     EISSN: 15408140     Source Type: Journal    
DOI: 10.1083/jcb.201411128     Document Type: Article

References (66)

1. AlQurashi, N., S.M. Hashimi, and M.Q. Wei. 2013. Chemical inhibitors and microRNAs (miRNA) targeting the mammalian target of rapamycin (mTOR) pathway: Potential for novel anticancer therapeutics. Int. J. Mol. Sci. 14:3874-3900. http://dx.doi.org/10.3390/ijms14023874
2. Askew, D.S., R.A. Ashmun, B.C. Simmons, and J.L. Cleveland. 1991. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene. 6:1915-1922.
3. Bai, X., and Y. Jiang. 2010. Key factors in mTOR regulation. Cell. Mol. Life Sci. 67:239-253. http://dx.doi.org/10.1007/s00018-009-0163-7
4. Benjamin, D., M. Colombi, C. Moroni, and M.N. Hall. 2011. Rapamycin passes the torch: A new generation of mTOR inhibitors. Nat. Rev. Drug Discov. 10:868-880. http://dx.doi.org/10.1038/nrd3531
5. Biswas, A.K., and D.G. Johnson. 2012. Transcriptional and nontranscriptional functions of E2F1 in response to DNA damage. Cancer Res. 72:13-17. http://dx.doi.org/10.1158/0008-5472.CAN-11-2196
6. Bronevetsky, Y., A.V. Villarino, C.J. Eisley, R. Barbeau, A.J. Barczak, G. A. Heinz, E. Kremmer, V. Heissmeyer, M.T. McManus, D.J. Erle, et al. 2013. T cell activation induces proteasomal degradation of Argonaute and rapid remodeling of the microRNA repertoire. J. Exp. Med. 210:417-432. http://dx.doi.org/10.1084/jem.20111717
7. Carew, J.S., K.R. Kelly, and S.T. Nawrocki. 2011. Mechanisms of mTOR inhibitor resistance in cancer therapy. Target Oncol. 6:17-27. http://dx.doi.org/10.1007/s11523-011-0167-8
8. Chen, P., C. Price, Z. Li, Y. Li, D. Cao, A. Wiley, C. He, S. Gurbuxani, R.B. Kunjamma, H. Huang, et al. 2013. miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia. Proc. Natl. Acad. Sci. USA. 110:11511-11516. http://dx.doi.org/10.1073/pnas.1310144110
9. Clark, A.S., K. West, S. Streicher, and P.A. Dennis. 2002. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol. Cancer Ther. 1:707-717.
10. Dancey, J. 2010. mTOR signaling and drug development in cancer. Nat Rev Clin Oncol. 7:209-219. http://dx.doi.org/10.1038/nrclinonc.2010.21
11. Engelmann, D., and B.M. Pützer. 2012. The dark side of E2F1: In transit beyond apoptosis. Cancer Res. 72:571-575. http://dx.doi.org/10.1158/0008-5472.CAN-11-2575
12. Feldman, M.E., B. Apsel, A. Uotila, R. Loewith, Z.A. Knight, D. Ruggero, and K.M. Shokat. 2009. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 7:e38.
13. Gill, R.M., T.V. Gabor, A.L. Couzens, and M.P. Scheid. 2013. The MYC-associated protein CDCA7 is phosphorylated by AKT to regulate MYC-dependent apoptosis and transformation. Mol. Cell. Biol. 33:498-513. http://dx.doi.org/10.1128/MCB.00276-12
14. Heller, G., M. Weinzierl, C. Noll, V. Babinsky, B. Ziegler, C. Altenberger, C. Minichsdorfer, G. Lang, B. Döme, A. End-Pfützenreuter, et al. 2012. Genome-wide miRNA expression profiling identifies miR-9-3 and miR-193a as targets for DNA methylation in non-small cell lung cancers. Clin. Cancer Res. 18:1619-1629. http://dx.doi.org/10.1158/1078-0432.CCR-11-2450
15. Huang, W.C., and M.C. Hung. 2009. Induction of Akt activity by chemotherapy confers acquired resistance. J. Formos. Med. Assoc. 108:180-194. http://dx.doi.org/10.1016/S0929-6646(09)60051-6
16. Hung, C.M., L. Garcia-Haro, C.A. Sparks, and D.A. Guertin. 2012. mTOR-dependent cell survival mechanisms. Cold Spring Harb. Perspect. Biol. 4:a008771. http://dx.doi.org/10.1101/cshperspect.a008771
17. Jacobsen, K.A., V.S. Prasad, C.L. Sidman, and D.G. Osmond. 1994. Apoptosis and macrophage-mediated deletion of precursor B cells in the bone marrow of E mu-myc transgenic mice. Blood. 84:2784-2794.
18. Jeon, H.M., Y.W. Sohn, S.Y. Oh, S.H. Kim, S. Beck, S. Kim, and H. Kim. 2011. ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9*-mediated suppression of SOX2. Cancer Res. 71:3410-3421. http://dx.doi.org/10.1158/0008-5472.CAN-10-3340
19. Jewell, J.L., R.C. Russell, and K.L. Guan. 2013. Amino acid signalling upstream of mTOR. Nat. Rev. Mol. Cell Biol. 14:133-139. http://dx.doi.org/10.1038/nrm3522
20. Jin, Y., S.D. Tymen, D. Chen, Z.J. Fang, Y. Zhao, D. Dragas, Y. Dai, P.T. Marucha, and X. Zhou. 2013. MicroRNA-99 family targets AKT/mTOR signaling pathway in dermal wound healing. PLoS One. 8:e64434. http://dx.doi.org/10.1371/journal.pone.0064434
21. Johnson, S.C., P.S. Rabinovitch, and M. Kaeberlein. 2013. mTOR is a key modulator of ageing and age-related disease. Nature. 493:338-345. http://dx.doi.org/10.1038/nature11861
22. Junttila, M.R., P. Puustinen, M. Niemelä, R. Ahola, H. Arnold, T. Böttzauw, R. Ala-aho, C. Nielsen, J. Ivaska, Y. Taya, et al. 2007. CIP2A inhibits PP2A in human malignancies. Cell. 130:51-62. http://dx.doi.org/10.1016/j.cell.2007.04.044
23. Knuefermann, C., Y. Lu, B. Liu, W. Jin, K. Liang, L. Wu, M. Schmidt, G.B. Mills, J. Mendelsohn, and Z. Fan. 2003. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene. 22:3205-3212. http://dx.doi.org/10.1038/sj.onc.1206394
24. Kovala, A.T., K.A. Harvey, P. McGlynn, G. Boguslawski, J.G. Garcia, and D. English. 2000. High-efficiency transient transfection of endothelial cells for functional analysis. FASEB J. 14:2486-2494. http://dx.doi.org/10.1096/fj.00-0147com
25. Krek, A., D. Grün, M.N. Poy, R. Wolf, L. Rosenberg, E.J. Epstein, P. MacMenamin, I. da Piedade, K.C. Gunsalus, M. Stoffel, and N. Rajewsky. 2005. Combinatorial microRNA target predictions. Nat. Genet. 37:495-500. http://dx.doi.org/10.1038/ng1536
26. Kurokawa, M., J. Kim, J. Geradts, K. Matsuura, L. Liu, X. Ran, W. Xia, TJ. Ribar, R. Henao, M.W. Dewhirst, et al. 2013. A network of substrates of the E3 ubiquitin ligases MDM2 and HUWE1 control apoptosis independently of p53. Sci. Signal. 6:ra32. http://dx.doi.org/10.1126/scisignal.2003741
27. Ladu, S., D.F. Calvisi, E.A. Conner, M. Farina, V.M. Factor, and S.S. Thorgeirsson. 2008. E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer. Gastroenterology. 135:1322-1332. http://dx.doi.org/10.1053Zj.gastro.2008.07.012
28. Laplante, M., and D.M. Sabatini. 2012. mTOR signaling in growth control and disease. Cell. 149:274-293. http://dx.doi.org/10.1016/j.cell.2012.03.017
29. Lee, K., L. Heffington, J. Jellusova, K.T. Nam, A. Ray buck, S.H. Cho, J.W. Thomas, R.C. Rickert, and M. Boothby. 2013. Requirement for Rictor in homeostasis and function of mature B lymphoid cells. Blood. 122:2369-2379. http://dx.doi.org/10.1182/blood-2013-01-477505
30. Letai, A., M.D. Sorcinelli, C. Beard, and S.J. Korsmeyer. 2004. Antiapoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell. 6:241-249. http://dx.doi.org/10.1016/j.ccr.2004.07.011
31. Ma, X.M., and J. Blenis. 2009. Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell Biol. 10:307-318. http://dx.doi.org/10.1038/nrm2672
32. Ma, L., J. Young, H. Prabhala, E. Pan, P. Mestdagh, D. Muth, J. Teruya-Feldstein, F. Reinhardt, T.T. Onder, S. Valastyan, et al. 2010. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat. Cell Biol. 12:247-256.
33. Martinez, L.A., E. Goluszko, H.Z. Chen, G. Leone, S. Post, G. Lozano, Z. Chen, and A. Chauchereau. 2010. E2F3 is a mediator of DNA damage-induced apoptosis. Mol. Cell. Biol. 30:524-536. http://dx.doi.org/10.1128/MCB.00938-09
34. McMahon, S.B. 2014. MYC and the control of apoptosis. Cold Spring Harb Perspect Med. 4:a014407. http://dx.doi.org/10.1101/cshperspect.a014407
35. Muller, P.A., and K.H. Vousden. 2014. Mutant p53 in cancer: New functions and therapeutic opportunities. Cancer Cell. 25:304-317. http://dx.doi.org/10.1016/j.ccr.2014.01.021
36. Neiman, P.E., S.J. Thomas, and G. Loring. 1991. Induction of apoptosis during normal and neoplastic B-cell development in the bursa of Fabricius. Proc. Natl. Acad. Sci. USA. 88:5857-5861. http://dx.doi.org/10.1073/pnas.88.13.5857
37. Oh, W.J., and E. Jacinto. 2011. mTOR complex 2 signaling and functions. Cell Cycle. 10:2305-2316. http://dx.doi.org/10.4161/cc.10.14.16586
38. Okamura, K., N. Liu, and E.C. Lai. 2009. Distinct mechanisms for microRNA strand selection by Drosophila Argonautes. Mol. Cell. 36:431-444. http://dx.doi.org/10.1016/j.molcel.2009.09.027
39. Ozdek, A., S. Sarac, M.U. Akyol, A. Sungur, and T. Yilmaz. 2004. c-myc and bcl-2 expression in supraglottic squamous cell carcinoma of the larynx. Otolaryngol. Head Neck Surg. 131:77-83. http://dx.doi.org/10.1016/j.otohns.2004.02.015
40. Pei, H., L. Li, B.L. Fridley, G.D. Jenkins, K.R. Kalari, W. Lingle, G. Petersen, Z. Lou, and L. Wang. 2009. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell. 16:259-266. http://dx.doi.org/10.1016/j.ccr.2009.07.016
41. Pencheva, N., and S.F. Tavazoie. 2013. Control of metastatic progression by microRNA regulatory networks. Nat. Cell Biol. 15:546-554. http://dx.doi.org/10.1038/ncb2769
42. Pützer, B.M., and D. Engelmann. 2013. E2F1 apoptosis counterattacked: Evil strikes back. Trends Mol. Med. 19:89-98. http://dx.doi.org/10.1016/j.molmed.2012.10.009
43. Rohn, J.L., A.O. Hueber, N.J. McCarthy, D. Lyon, P. Navarro, B.M. Burgering, and G.I. Evan. 1998. The opposing roles of the Akt and c-Myc signalling pathways in survival from CD95-mediated apoptosis. Oncogene. 17:2811-2818. http://dx.doi.org/10.1038/sj.onc.1202393
44. Sarbassov, D.D., S.M. Ali, D.H. Kim, D.A. Guertin, R.R. Latek, H. Erdjument-Bromage, P. Tempst, and D.M. Sabatini. 2004. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14:1296-1302. http://dx.doi.org/10.1016/j.cub.2004.06.054
45. Sarbassov, D.D., D.A. Guertin, S.M. Ali, and D.M. Sabatini. 2005. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 307:1098-1101. http://dx.doi.org/10.1126/science.1106148
46. Sellers, W.R., B.G. Novitch, S. Miyake, A. Heith, G.A. Otterson, F.J. Kaye, A. B. Lassar, and W.G. Kaelin Jr. 1998. Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth. Genes Dev. 12:95-106. http://dx.doi.org/10.1101/gad.12.1.95
47. Shi, Y., J.M. Glynn, L.J. Guilbert, T.G. Cotter, R.P. Bissonnette, and D.R. Green. 1992. Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. Science. 257:212-214. http://dx.doi.org/10.1126/science.1378649
48. Sparks, C.A., and D.A. Guertin. 2010. Targeting mTOR: Prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene. 29:3733-3744. http://dx.doi.org/10.1038/onc.2010.139
49. Stanelle, J., and B.M. Pützer. 2006. E2F1-induced apoptosis: Turning killers into therapeutics. Trends Mol. Med. 12:177-185. http://dx.doi.org/10.1016/j.molmed.2006.02.002
50. Sun, Y., Y. Ge, J. Drnevich, Y. Zhao, M. Band, and J. Chen. 2010. Mammalian target of rapamycin regulates miRNA-1 and follistatin in skeletal myogenesis. J. Cell Biol. 189:1157-1169. http://dx.doi.org/10.1083/jcb.200912093
51. Thum, T., C. Gross, J. Fiedler, T. Fischer, S. Kissler, M. Bussen, P. Galuppo, S. Just, W. Rottbauer, S. Frantz, et al. 2008. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 456:980-984. http://dx.doi.org/10.1038/nature07511
52. Totary-Jain, H., and A.R. Marks. 2013. MicroRNAs and the cellular response to rapamycin: Potential role in diagnosis and therapy. Cell Cycle. 12:861862. http://dx.doi.org/10.4161/cc.24100
53. Totary-Jain, H., D. Sanoudou, I.Z. Ben-Dov, C.N. Dautriche, P. Guarnieri, S.O. Marx, T. Tuschl, and A.R. Marks. 2013. Reprogramming of the microRNA transcriptome mediates resistance to rapamycin. J. Biol. Chem. 288:6034-6044. http://dx.doi.org/10.1074/jbc.M112.416446
54. Trindade, A.J., D.A. Medvetz, N.A. Neuman, F. Myachina, J. Yu, C. Priolo, and E. P Henske. 2013. MicroRNA-21 is induced by rapamycin in a model of tuberous sclerosis (TSC) and lymphangioleiomyomatosis (LAM). PLoS One. 8:e60014. http://dx.doi.org/10.1371/journal.pone.0060014
55. Uesugi, A., K. Kozaki, T. Tsuruta, M. Furuta, K. Morita, I. Imoto, K. Omura, and J. Inazawa. 2011. The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res. 71:5765-5778. http://dx.doi.org/10.1158/0008-5472.CAN-11-0368
56. Wahlquist, C., D. Jeong, A. Rojas-Munoz, C. Kho, A. Lee, S. Mitsuyama, A. van Mil, W.J. Park, J.P. Sluijter, PA. Doevendans, et al. 2014. Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature. 508:531-535. http://dx.doi.org/10.1038/nature13073
57. Walker, S.M., G.C. Meinke, and W.O. Weigle. 1979. Separation of various B-cell subpopulations from mouse spleen. I. Depletion of B cells by rosetting with glutaraldehyde-fixed, anti-immunoglobulin-coupled red blood cells. Cell. Immunol 46:158-169. http://dx.doi.org/10.1016/0008-8749(79)90253-3
58. Wander, S.A., B.T. Hennessy, and J.M. Slingerland. 2011. Next-generation mTOR inhibitors in clinical oncology: How pathway complexity informs therapeutic strategy. J. Clin. Invest. 121:1231-1241. http://dx.doi.org/10.1172/JC144145
59. Westmoreland, J.J., Q. Wang, M. Bouzaffour, S.J. Baker, and B. Sosa-Pineda. 2009. Pdk1 activity controls proliferation, survival, and growth of developing pancreatic cells. Dev. Biol. 334:285-298. http://dx.doi.org/10.1016/j.ydbio.2009.07.030
60. Wyllie, A.H., K.A. Rose, R.G. Morris, C.M. Steel, E. Foster, and D.A. Spandidos. 1987. Rodent fibroblast tumours expressing human myc and ras genes: Growth, metastasis and endogenous oncogene expression. Br. J. Cancer. 56:251-259. http://dx.doi.org/10.1038/bjc.1987.186
61. Yeh, E., M. Cunningham, H. Arnold, D. Chasse, T. Monteith, G. Ivaldi, W.C. Hahn, P.T. Stukenberg, S. Shenolikar, T. Uchida, et al. 2004. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat. Cell Biol. 6:308-318. http://dx.doi.org/10.1038/ncb1110
62. Yeh, E.S., G.K. Belka, A.E. Vernon, C.C. Chen, J.J. Jung, and L.A. Chodosh. 2013. Hunk negatively regulates c-myc to promote Akt-mediated cell survival and mammary tumorigenesis induced by loss of Pten. Proc. Natl. Acad. Sci. USA. 110:6103-6108. http://dx.doi.org/10.1073/pnas.1217415110
63. Yuva-Aydemir, Y, A. Simkin, E. Gascon, and F.B. Gao. 2011. MicroRNA-9: Functional evolution of a conserved small regulatory RNA. RNA Biol. 8:557-564. http://dx.doi.org/10.4161/rna.8.4.16019
64. Zawistowski, J.S., K. Nakamura, J.S. Parker, D.A. Granger, B.T. Golitz, and G. L. Johnson. 2013. MicroRNA 9-3p targets p1 integrin to sensitize claudin-low breast cancer cells to MEK inhibition. Mol. Cell. Biol. 33:2260-2274. http://dx.doi.org/10.1128/MCB.00269-13
65. Zheng, C., Z. Ren, H. Wang, W. Zhang, D.V. Kalvakolanu, Z. Tian, and W. Xiao. 2009. E2F1 Induces tumor cell survival via nuclear factor-KB-dependent induction of EGR1 transcription in prostate cancer cells. Cancer Res. 69:2324-2331. http://dx.doi.org/10.1158/0008-5472.CAN-08-4113
66. Zindy, F., C.M. Eischen, D.H. Randle, T. Kamijo, J.L. Cleveland, C.J. Sherr, and M.F. Roussel. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12:2424-2433. http://dx.doi.org/10.1101/gad.12.15.2424